These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 15787290)

  • 21. [Tumor recurrence in the salvaged breast; a second chance?].
    Roukema JA; Dolman A; Maat B
    Ned Tijdschr Geneeskd; 1989 Dec; 133(52):2593-5. PubMed ID: 2558321
    [No Abstract]   [Full Text] [Related]  

  • 22. Some clarity in the management of DCIS in breast cancer screening.
    Wald NJ
    J Med Screen; 2011; 18(3):112. PubMed ID: 22045817
    [No Abstract]   [Full Text] [Related]  

  • 23. [Value of radiotherapy in breast cancer. Breast preservation rises to 80%].
    Seegenschmiedt MH; Strittmatter HJ
    MMW Fortschr Med; 2003 Jun; 145(25):26-30. PubMed ID: 12891848
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ductal carcinoma in situ and microinvasive disease. American College of Radiology. ACR Appropriateness Criteria.
    Rabinovitch RA; Solin LJ; Shank BM; Haffty BG; Halberg FE; Martinez AA; McCormick B; McNeese MD; Mendenhall NP; Mitchell SE; Taylor ME; Singletary SE; Leibel S
    Radiology; 2000 Jun; 215 Suppl():1137-52. PubMed ID: 11037538
    [No Abstract]   [Full Text] [Related]  

  • 25. Disparities in the application of adjuvant radiotherapy after breast-conserving surgery for early stage breast cancer: impact on overall survival.
    Dragun AE; Huang B; Tucker TC; Spanos WJ
    Cancer; 2011 Jun; 117(12):2590-8. PubMed ID: 21656737
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Breast cancer: non-metastatic.
    Dixon JM; Gregory K; Johnston S; Rodger A
    Clin Evid; 2002 Dec; (8):1811-39. PubMed ID: 12603971
    [No Abstract]   [Full Text] [Related]  

  • 27. Ductal carcinoma in situ of the breast: our experience.
    Ruggiero R; Procaccini E; Sanguinetti A; Cremone C; Gili S; Docimo G; Docimo L; Sparavigna L; Gubitosi A; Parmeggiani D; Avenia N
    G Chir; 2009 Mar; 30(3):121-4. PubMed ID: 19351465
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Breast cancer: strategies for the 1990's.
    Borgen PI; Kinne DW
    Compr Ther; 1992 Jun; 18(6):24-9. PubMed ID: 1324825
    [No Abstract]   [Full Text] [Related]  

  • 29. Role of endocrine responsiveness and HER2/neu overexpression in inflammatory breast cancer treated with multimodality preoperative therapy.
    D'Alessandro C; Dellapasqua S; Orlando L; Santoro L; Maisonneuve P; Torrisi R; Balduzzi A; Scarano E; Ghisini R; Peruzzotti G; Goldhirsch A; Colleoni M
    Breast J; 2008; 14(5):435-41. PubMed ID: 18821931
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrative tumor board: recurrent breast cancer or new primary? Case Presentation.
    Schmaltz J
    Integr Cancer Ther; 2003 Sep; 2(3):268-70. PubMed ID: 15035889
    [No Abstract]   [Full Text] [Related]  

  • 31. [Breast carcinoma--breast preservation as a therapeutic principle].
    Greiner RH
    Ther Umsch; 1998 Jul; 55(7):408-11. PubMed ID: 9702105
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Limitations of sentinel lymph node biopsy in breast cancer].
    Fehr MK
    Gynakol Geburtshilfliche Rundsch; 2005 Jun; 45(3):127-31. PubMed ID: 15990436
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Re: Trends in the treatment of ductal carcinoma in situ of the breast.
    Zorbas H; Luxford K; Evans A; Villanueva EV
    J Natl Cancer Inst; 2004 Aug; 96(16):1258; author reply 1259-60. PubMed ID: 15316063
    [No Abstract]   [Full Text] [Related]  

  • 34. Re: Trends in the treatment of ductal carcinoma in situ of the breast.
    Schwartz GF; Lagios MD; Silverstein MJ
    J Natl Cancer Inst; 2004 Aug; 96(16):1258-9; author reply 1259-60. PubMed ID: 15316064
    [No Abstract]   [Full Text] [Related]  

  • 35. Factors predicting in-breast tumor recurrence after breast-conserving surgery.
    Mechera R; Viehl CT; Oertli D
    Breast Cancer Res Treat; 2009 Jul; 116(1):171-7. PubMed ID: 18815880
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does neoadjuvant/adjuvant chemotherapy change the natural history of classic invasive lobular carcinoma?
    Katz A
    J Clin Oncol; 2005 Sep; 23(27):6796; author reply 6796-7. PubMed ID: 16170189
    [No Abstract]   [Full Text] [Related]  

  • 37. NCCN Task Force Report: Adjuvant Therapy for Breast Cancer.
    Carlson RW; Brown E; Burstein HJ; Gradishar WJ; Hudis CA; Loprinzi C; Mamounas EP; Perez EA; Pritchard K; Ravdin P; Recht A; Somlo G; Theriault RL; Winer EP; Wolff AC;
    J Natl Compr Canc Netw; 2006 Mar; 4 Suppl 1():S1-26. PubMed ID: 16507275
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The management of early breast carcinoma before and after the introduction of clinical practice guidelines.
    White V; Pruden M; Giles G; Collins J; Jamrozik K; Inglis G; Boyages J; Hill D
    Cancer; 2004 Aug; 101(3):476-85. PubMed ID: 15274060
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Guideline 'Treatment of breast cancer 2008' (revision)].
    Struikmans H; Nortier JW; Rutgers EJ; Zonderland HM; Bontenbal M; Elkhuizen PH; van Tienhoven G; Tjan-Heijnen VC; van Vegchel T; Tuut MK; Benraadt J
    Ned Tijdschr Geneeskd; 2008 Nov; 152(46):2507-11. PubMed ID: 19055257
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Long-term results of breast-conservation therapy for breast neoplasms].
    Ogawa T; Kanauchi H; Tsuji E; Kurabayashi R; Kaminishi M
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():422-7. PubMed ID: 17682187
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.